Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
Vericel (NASDAQ:VCEL) Corp’s stock reached a 52-week low, trading at 34.49 USD, marking a significant drop from its 52-week high of 63 USD. According to InvestingPro data, the company maintains strong financial health with a current ratio of 4.97x, indicating robust liquidity. This milestone reflects a challenging year for the company, as the stock has experienced a significant decline, with a 1-year change of -26.63%. Despite the recent pressure, analysts remain optimistic, with targets ranging from 49 USD to 67 USD. The drop to this 52-week low highlights the volatility and pressures faced by Vericel in the market over the past year, as investors continue to assess the company’s performance and future prospects. For deeper insights and 13 additional ProTips on Vericel, including detailed valuation metrics and growth indicators, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Vericel Corporation reported its second-quarter earnings for 2025, showing a narrowed net loss and an increase in revenue. The earnings per share (EPS) was a loss of $0.01, which surpassed analyst projections of a $0.03 loss. However, the revenue came in slightly below expectations at $63.24 million, compared to the anticipated $64.61 million. Despite these financial results, Canaccord Genuity adjusted its price target for Vericel’s stock from $61.00 to $58.00, maintaining a Buy rating. The adjustment was influenced by mixed performance across Vericel’s product lines. While the company exceeded bottom-line expectations, its MACI product fell short of revenue targets. Additionally, Epicel’s revenue was lower than expected, despite achieving the highest number of biopsies in any quarter since 2023. These developments reflect Vericel’s ongoing challenges and achievements within its market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.